ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and SingaporeBusiness Wire • 12/14/20
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/30/20
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 11/20/20
ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business HighlightsBusiness Wire • 11/12/20
ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020Business Wire • 11/05/20
ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/04/20
ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid TumorsBusiness Wire • 11/03/20
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)GlobeNewsWire • 10/30/20
ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common SharesBusiness Wire • 10/09/20
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 09/21/20
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020Business Wire • 09/17/20
ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor CancersBusiness Wire • 09/10/20
ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131Business Wire • 09/05/20
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/19/20
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsBusiness Wire • 08/18/20
ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020Business Wire • 08/12/20
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With IbrutinibBusiness Wire • 07/17/20
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab TesirineBusiness Wire • 07/06/20
